CORDIS
EU research results

CORDIS

English EN
GEnetic NEtworks as a tool for anti-CAncer Drug Development

GEnetic NEtworks as a tool for anti-CAncer Drug Development

Objective

Although several therapies target cellular pathways, current small molecules drug discovery is based on identification of inhibitors to single proteins, without knowledge of whether they are the most advantageous target. The objective of this proposal is to develop a novel method for drug discovery, combining phenotypic cell based screens with functional genetic networks to determine the molecular mechanisms of numerous small molecule inhibitors. This method will enable identification of numerous distinct inhibitors of a particular pathway, as well as providing their molecular mechanism.

Cancer cells harbour gene mutations that make them more reliant on other cellular pathways for survival. Such cellular pathways can be targeted to selectively kill the cancer cells using the concept of synthetic lethality. In this project we want to identify inhibitors of homologous recombination to target cancer using synthetic lethality.

To establish a functional genetic network for homologous recombination, we will first identify all recombination proteins using multiple genome-wide RNAi screens. Then the synthetic sick or lethal interaction map between all recombination proteins is determined by co-depletion of these. Such synthetic sick or lethal network will identify numerous putative targets for anti-cancer treatment. Importantly, using this network for chemical-genetic functional interactions will assist in determinating of the molecular mechanisms of inhibitors. Chemical-genetic networks based on synthetic sickness or lethality can potentially change future drug discovery methods as well as providing new mechanistic insights into the field of toxicology.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Principal Investigator

Ulf Thomas Edvard Helleday (Prof.)

Host institution

KAROLINSKA INSTITUTET

Address

Nobels Vag 5
17177 Stockholm

Sweden

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 927 049,20

Principal Investigator

Ulf Thomas Edvard Helleday (Prof.)

Administrative Contact

Jill Blomstrand (Mrs.)

Beneficiaries (2)

Sort alphabetically

Sort by EU Contribution

Expand all

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 1 927 049,20

STOCKHOLMS UNIVERSITET

Sweden

EU Contribution

€ 572 950,80

Project information

Grant agreement ID: 268815

Status

Closed project

  • Start date

    1 March 2011

  • End date

    29 February 2016

Funded under:

FP7-IDEAS-ERC

  • Overall budget:

    € 2 500 000

  • EU contribution

    € 2 500 000

Hosted by:

KAROLINSKA INSTITUTET

Sweden